Pharmaceutical dosage forms fabricated with nanomaterials

• US 10,060,860 B2
• Filed: 02/05/2016
• Issued: 08/28/2018
• Est. Priority Date: 06/30/2007
• Status: Active Grant

• Current Assignee: SMP Logic Systems LLC
• Original Assignee: SMP Logic Systems LLC
• Inventors: Popp, Shane M.
• Primary Examiner(s): Richter, Johann R
• Assistant Examiner(s): Alley, Genevieve S
• Application Number:
  US14/998,716
• Publication Number:
  US 20160245759A1
• Time in Patent Office: 935 Days
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/5107 Excipients; Inactive ingredients
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: B82Y 15/00 Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• CPC Class Codes: G01N 21/80 Indicating pH value
• CPC Class Codes: G01N 21/9508 Capsules; Tablets

Abstract

Nanomaterials fabricated to pharmaceutical dosage forms are disclosed. The nanomaterials are useful to provide a plurality of analysis to the dosage form. Consequently, the nanomaterials provide a means to perform quality testing on a continuous basis throughout the supply chain, including the cold chain whereby manufacturers and distributors can achieve greater product integrity and longer shelf life and ultimately minimize cost. The end user benefits in obtaining the highest quality drugs at the time of need.

Claims

1. A method of fabricating a nanomaterial into a pharmaceutical dosage form, said method comprising,

a) fabricating a nanomaterial which possesses the functional property of thermal conductivity, to a pharmaceutical dosage form, wherein said dosage form is a pre-filled syringe and wherein said fabricating creates an interface between said nanomaterial and a drug product enclosed within the pre-filled syringe;

b) interfacing the nanomaterial with a drug product enclosed within the pre-filled syringe, wherein said interfacing creates a boundary between the nanomaterial and said drug product;

c) enclosing the drug product into the pre-filled syringe, whereby the nanomaterial monitors a drug product property within the pre-filled syringe, and wherein the drug product property is temperature.

2. The method claim 1, wherein the nanomaterial comprises a nanofiller or nanocomposite.

3. The method of claim 2, further comprising a thermal biosensor.

4. The method of claim 2, further comprising a polyhedral oligomeric silsequioxane or colloidal silica.

5. The method of claim 1, wherein the drug product is a vaccine.